Can severe pulmonary hypertension with an estimated right ventricular systolic pressure of 80–90 mmHg lead to right‑sided heart failure and ventricular tachycardia episodes?

Yes, Severe Pulmonary Hypertension Directly Causes Right-Sided Heart Failure and Can Lead to Ventricular Arrhythmias

Pulmonary hypertension with RVSP of 80–90 mmHg absolutely leads to right-sided heart failure, and ventricular tachycardia episodes are a recognized, though less common, complication of this disease process. 1

Right-Sided Heart Failure: The Primary Consequence

The American Heart Association definitively states that chronic right heart failure is the principal cause of death in patients with pulmonary arterial hypertension 1. The pathophysiology is straightforward:

• Pressure overload from severe PH (your patient's RVSP of 80–90 mmHg represents severe elevation) creates chronic afterload stress on the right ventricle
• This triggers progressive RV remodeling including hypertrophy, dilatation, and fibrosis
• The RV eventually fails to maintain adequate cardiac output despite adequate preload
• Clinical manifestations include:
  • Decreased exercise tolerance and poor functional capacity
  • Progressive end-organ damage from venous congestion and underperfusion
  • Abdominal distension and ankle edema
  • Cachexia from poor nutrient absorption 1

The ESC/ERS guidelines confirm that symptoms of PH are primarily related to progressive RV dysfunction, with abdominal distension and ankle edema developing as RV failure progresses 2.

Ventricular Tachycardia: A Real but Less Common Complication

Ventricular arrhythmias, including VT, do occur in pulmonary hypertension and carry important prognostic implications, though they are less frequent than atrial arrhythmias 3, 4.

Epidemiology of VT in PH:

• Prevalence: 18% of PH-left heart failure patients experience clinically significant ventricular tachyarrhythmias 4
• Premature ventricular contractions and non-sustained VT are most common
• Sustained VT and ventricular fibrillation are uncommon but do occur 3
• VT prevalence increases disproportionately with PH severity 4

Mechanisms Creating VT Substrate:

The severe RV remodeling in your patient creates multiple arrhythmogenic mechanisms 3, 5:

1. Structural remodeling: RV hypertrophy, fibrosis, and gap junction alterations
2. Ion channel changes: Specific alterations in RV ion channels
3. Calcium handling abnormalities: Disrupted intracellular calcium regulation
4. RV ischemia: From capillary rarefaction and decreased right coronary perfusion
5. Autonomic imbalance: Increased sympathetic tone with prolonged action potentials
6. Metabolic derangements: Aerobic glycolysis and glutaminolysis similar to cancer cells
7. Inflammation and oxidative stress

Critical Predictor:

TAPSE <16 mm is a potent independent predictor of VT (OR 3.25,95% CI 2.38-4.45), largely independent of left ventricular ejection fraction 4. This "right heart phenotype" drives malignant ventricular arrhythmias and mortality.

Prognostic Implications

VT carries the highest mortality risk among arrhythmias in PH-heart failure patients (HR 2.56,95% CI 1.95-3.36 for all-cause mortality) 4. This is distinct from atrial arrhythmias, which primarily drive rehospitalization rather than death.

Clinical Pitfalls to Avoid

1. Don't dismiss VT as unrelated to PH: The arrhythmia burden is substantial (68.9% overall arrhythmia prevalence) and biologically linked to RV dysfunction 4

2. Monitor RV function, not just pressures: TAPSE, fractional area change, and RV free-wall strain are critical for risk stratification 4

3. Recognize maladaptive vs. adaptive RVH: Look for:

   • Elevated NT-proBNP and troponin
   • RV dilatation on echo
   • QTc prolongation on ECG
   • These indicate maladaptive remodeling with higher arrhythmia risk 5

4. The systemic nature is often underestimated: RV failure affects multiple organ systems through reduced perfusion, congestion, neurohormonal activation, and oxidative stress 6

Management Considerations

While the guidelines note that specific therapies promoting RV function stabilization are lacking 1, the arrhythmia management includes:

• Amiodarone is the preferred antiarrhythmic in PH patients 7
• Electrophysiological interventions (cardioversion, ablation) are safe in PH 7
• Address the underlying PH aggressively to reduce RV afterload
• Consider RV monitoring as a tool for sudden cardiac death risk stratification 4

The key message: Your patient's severe PH with RVSP 80–90 mmHg creates both the hemodynamic conditions for right heart failure AND the electrophysiological substrate for ventricular arrhythmias through shared mechanisms of RV remodeling, ischemia, and metabolic dysfunction.